Inventor · disambiguated record
Stefan Sperl
Also filed as: SPERL STEFAN
14 granted patents·7 pending applications·131 citations·filing 2000–2025
92Inventor score
Files withWILEX AG11KIORA PHARMACEUTICALS GMBH4PANOPTES PHARMA GES M B H2KIORA PHARMACEUTICALS PTY LTD1MAX PLANCK GESSELLSCHAFT ZUR F1
Top patents by PatentIndex Score
21 records- 0192US7208521B2Selective inhibitors of the urokinase plasminogen activatorWILEX AG·Filed 2005·Granted Apr 24, 2007·13 cites·38 claims
- 0291US7608623B2Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitorsWILEX AG·Filed 2005·Granted Oct 27, 2009·25 cites·6 claims
- 0387US7659396B2Method for the production of phenylalanine derivativesWILEX AG·Filed 2007·Granted Feb 9, 2010·8 cites·4 claims
- 0486US6841702B2Highly selective inhibitors of the urokinase plasminogen activatorWILEX BIOTECHNOLOGY GMBH·Filed 2001·Granted Jan 11, 2005·26 cites·10 claims
- 0584US7807681B2Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitorsWILEX AG·Filed 2008·Granted Oct 5, 2010·8 cites·8 claims
- 0684US7038074B2Arginine mimetics as factor Xa inhibitorsWILEX AG·Filed 2001·Granted May 2, 2006·13 cites·10 claims
- 0783US12209073B2Polymorphs of a dihydroorotate dehydrogenase (DHOD) inhibitorKIORA PHARMACEUTICALS GMBH·Filed 2023·Granted Jan 28, 2025·2 cites·20 claims
- 0882US7049460B1Selective inhibitors of the urokinase plasminogen activatorWILEX AG·Filed 2000·Granted May 23, 2006·13 cites·32 claims
- 0978US11730716B2Compounds for treating ophthalmic diseases and disordersPANOPTES PHARMA GES M B H·Filed 2015·Granted Aug 22, 2023·2 cites·9 claims
- 1077US7538216B2Guanidino phenylalanin compounds used as urokinase inhibitorsWILEX AG·Filed 2003·Granted May 26, 2009·11 cites·15 claims
- 1175US7247724B2Method for the production of phenylalanine derivativesWILEX AG·Filed 2003·Granted Jul 24, 2007·8 cites·5 claims
- 1273US12364680B2Compounds for treating ophthalmic diseases and disordersKIORA PHARMACEUTICALS GMBH·Filed 2023·Granted Jul 22, 2025·0 cites·16 claims
- 1370US2025381167A1Compounds for treating ophthalmic diseases and disordersKIORA PHARMACEUTICALS GMBH·Filed 2025·Application pending·0 cites
- 1469US7049344B2Highly selective inhibitors of the urokinase plasminogen activatorMAX PLANCK GESSELLSCHAFT ZUR F·Filed 2004·Granted May 23, 2006·2 cites·15 claims
- 1562US2010068272A1Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitorsWILEX AG·Filed 2009·Application pending·0 cites
- 1661US2024358544A1Method of treating vision loss in a human subject with photoreactive compoundsKIORA PHARMACEUTICALS PTY LTD·Filed 2024·Application pending·0 cites
- 1756US12472263B2Ophthalmic formulationPANOPTES PHARMA GES M B H·Filed 2019·Granted Nov 18, 2025·0 cites·12 claims
- 1851US2006189689A1Arginine mimetics as factor Xa inhibitorsWILEX AG·Filed 2006·Application pending·0 cites
- 1949US2023278979A1Salts of a dihydroorotate dehydrogenase (dhod) inhibitorKIORA PHARMACEUTICALS GMBH·Filed 2023·Application pending·0 cites
- 2046US2004266766A1Selective urokinase inhibitorsWILEX AG·Filed 2004·Application pending·0 cites
- 2138US2009286837A1Oxadiazole compounds as urokinase inhibitorsSPERL STEFAN·Filed 2006·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Stefan Sperl files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →